Raghavan Vijay, Vijayaraghavalu Sivakumar, Peetla Chiranjeevi, Yamada Masayoshi, Morisada Megan, Labhasetwar Vinod
Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic , 9500 Euclid Avenue, Cleveland, Ohio 44195, United States.
Taussig Cancer Institute, Cleveland Clinic , Cleveland, Ohio 44195, United States.
Langmuir. 2015 Oct 27;31(42):11564-73. doi: 10.1021/acs.langmuir.5b02601. Epub 2015 Oct 15.
Cell-membrane lipid composition can greatly influence biophysical properties of cell membranes, affecting various cellular functions. We previously showed that lipid synthesis becomes altered in the membranes of resistant breast cancer cells (MCF-7/ADR); they form a more rigid, hydrophobic lipid monolayer than do sensitive cell membranes (MCF-7). These changes in membrane lipids of resistant cells, attributed to epigenetic aberration, significantly affected drug transport and endocytic function, thus impacting the efficacy of anticancer drugs. The present study's objective was to determine the effects of the epigenetic drug, 5-aza-2'-deoxycytidine (DAC), delivered in sustained-release nanogels (DAC-NGs), on the composition and biophysical properties of membrane lipids of resistant cells. Resistant and sensitive cells were treated with DAC in solution (DAC-sol) or DAC-NGs, and cell-membrane lipids were isolated and analyzed for lipid composition and biophysical properties. In resistant cells, we found increased formation of cholesterol-sphingomyelin (CHOL-SM) rafts with culturing time, whereas DAC treatment reduced their formation. In general, the effect of DAC-NGs was greater in changing the lipid composition than with DAC-sol. DAC treatment also caused a rise in levels of certain phospholipids and neutral lipids known to increase membrane fluidity, while reducing the levels of certain lipids known to increase membrane rigidity. Isotherm data showed increased lipid membrane fluidity following DAC treatment, attributed to decrease levels of CHOL-SM rafts (lamellar beta [Lβ] structures or ordered gel) and a corresponding increase in lipids that form lamellar alpha-structures (Lα, liquid crystalline phase). Sensitive cells showed marginal or insignificant changes in lipid profile following DAC-treatment, suggesting that epigenetic changes affecting lipid biosynthesis are more specific to resistant cells. Since membrane fluidity plays a major role in drug transport and endocytic function, treatment of resistant cells with epigenetic drugs with altered lipid profile could facilitate anticancer drug transport to overcome acquired drug resistance in a combination therapy.
细胞膜脂质组成可极大地影响细胞膜的生物物理特性,进而影响各种细胞功能。我们之前发现,耐药乳腺癌细胞(MCF-7/ADR)的细胞膜中脂质合成发生了改变;与敏感细胞膜(MCF-7)相比,它们形成了更刚性、疏水性更强的脂质单层。耐药细胞的膜脂质这些变化归因于表观遗传畸变,显著影响了药物转运和内吞功能,从而影响了抗癌药物的疗效。本研究的目的是确定以缓释纳米凝胶(DAC-NGs)形式递送的表观遗传药物5-氮杂-2'-脱氧胞苷(DAC)对耐药细胞的膜脂质组成和生物物理特性的影响。用溶液中的DAC(DAC-sol)或DAC-NGs处理耐药和敏感细胞,分离细胞膜脂质并分析其脂质组成和生物物理特性。在耐药细胞中,我们发现随着培养时间的延长,胆固醇-鞘磷脂(CHOL-SM)筏的形成增加,而DAC处理减少了它们的形成。一般来说,DAC-NGs在改变脂质组成方面的效果比DAC-sol更大。DAC处理还导致某些已知可增加膜流动性的磷脂和中性脂质水平升高,同时降低某些已知可增加膜刚性的脂质水平。等温线数据显示,DAC处理后脂质膜流动性增加,这归因于CHOL-SM筏(层状β[Lβ]结构或有序凝胶)水平降低以及形成层状α结构(Lα,液晶相)的脂质相应增加。DAC处理后,敏感细胞的脂质谱变化很小或不明显,这表明影响脂质生物合成的表观遗传变化对耐药细胞更具特异性。由于膜流动性在药物转运和内吞功能中起主要作用,用脂质谱改变的表观遗传药物治疗耐药细胞可能有助于抗癌药物转运,从而在联合治疗中克服获得性耐药。